# A study of radiotherapy with or without chemotherapy in primary central nervous system (CNS) lymphoma

Submission date	<b>Recruitment status</b> Stopped	Prospectively registered			
28/02/2001		☐ Protocol			
Registration date	Overall study status	Statistical analysis plan			
28/02/2001	Stopped	[X] Results			
Last Edited	<b>Condition category</b> Cancer	Individual participant data			
29/07/2009		☐ Record updated in last year			

# Plain English summary of protocol

Not provided at time of registration

## Contact information

#### Type(s)

Scientific

#### Contact name

Miss Sally Stenning

#### Contact details

MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA ss@ctu.mrc.ac.uk

# Additional identifiers

Protocol serial number BR06

# Study information

Scientific Title

#### **Study objectives**

To evaluate the effect of CHOP chemotherapy on event-free and overall survival.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

#### Health condition(s) or problem(s) studied

Cancer

#### **Interventions**

Group 1: radiotherapy alone (54 Gy total dose in 27 fractions)

Group 2: radiotherapy as above, followed after 4 weeks by six cycles of CHOP chemotherapy given at 3-week intervals (cyclophosphamide 750 mg/m^2 iv, adriamycin 50 mg/m^2 iv, vincristine 1.4 mg/m^2 iv (max 2 mg) and prednisolone (20 mg po tds for 5 days)

#### Intervention Type

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

CHOP chemotherapy

#### Primary outcome(s)

Survival.

#### Key secondary outcome(s))

Event-free survival.

#### Completion date

01/10/1995

## Reason abandoned (if study stopped)

Slow accrual

# **Eligibility**

#### Key inclusion criteria

- 1. Pathologically proven primary cerebral lymphoma
- 2. Aged 18-75
- 3. No previous radiotherapy or chemotherapy
- 4. Adequate neurological, physical and mental function

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

18 years

#### Upper age limit

75 years

#### Sex

**Not Specified** 

#### Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/11/1988

#### Date of final enrolment

01/10/1995

# **Locations**

#### Countries of recruitment

**United Kingdom** 

England

# Study participating centre MRC Clinical Trials Unit

London United Kingdom NW1 2DA

# Sponsor information

#### Organisation

Medical Research Council (MRC) (UK)

# Funder(s)

#### Funder type

Research council

#### **Funder Name**

Medical Research Council (MRC) (UK)

#### Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

National government

#### Location

**United Kingdom** 

# **Results and Publications**

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type	Details	Date created	 Peer reviewed?	Patient- facing?
<u>article</u>	results in: GM Mead, NM Bleehen, A Gregor, J Bullimore, R Rampling, JT Roberts, M Glaser, P Lantos, JW Ironside, TH Moss, M Brada, JB Whaley and SP Stenning for the MRC Brain Tumour Working Party (). A Medical Research Council Randomised Trial in patients with primary cerebral non-Hodgkin lymphoma. Cancer 89(6): 1359-1370	15/09 /2000	Yes	No